Exploring 3D Printing in Drug Development: Assessing the Potential of Advanced Melt Drop Deposition Technology for Solubility Enhancement by Creation of Amorphous Solid Dispersions

<b>Background:</b> Melt-based 3D printing technologies are currently extensively evaluated for research purposes as well as for industrial applications. Classical approaches often require intermediates, which can pose a risk to stability and add additional complexity to the process. The...

Full description

Saved in:
Bibliographic Details
Main Authors: Nabil Lamrabet, Florian Hess, Philip Leidig, Andreas Marx, Thomas Kipping
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/16/12/1501
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846103227210137600
author Nabil Lamrabet
Florian Hess
Philip Leidig
Andreas Marx
Thomas Kipping
author_facet Nabil Lamrabet
Florian Hess
Philip Leidig
Andreas Marx
Thomas Kipping
author_sort Nabil Lamrabet
collection DOAJ
description <b>Background:</b> Melt-based 3D printing technologies are currently extensively evaluated for research purposes as well as for industrial applications. Classical approaches often require intermediates, which can pose a risk to stability and add additional complexity to the process. The Advanced Melt Drop Deposition (AMDD) technology, is a 3D printing process that combines the principles of melt extrusion with pressure-driven ejection, similar to injection molding. This method offers several advantages over traditional melt-based 3D printing techniques, making it particularly suitable for pharmaceutical applications. <b>Objectives:</b> This study evaluates the AMDD printing system for producing solid oral dosage forms, with a primary focus on the thermo-stable polymer polyvinyl alcohol (PVA). The suitability of AMDD technology for creating amorphous solid dispersions (ASDs) is also examined. Finally, the study aims to define the material requirements and limitations of the raw materials used in the process. <b>Methods:</b> The active pharmaceutical ingredients (APIs) indometacin and ketoconazole were used, with PVA 4-88 serving as the carrier polymer. Powders, wet granulates, and pellets were investigated as raw materials and characterized. Dissolution testing and content analyses were performed on the printed dosage forms. Solid-state characterization was conducted using differential scanning calorimetry (DSC) and X-ray diffraction (XRD). Degradation due to thermal and mechanical stress was analyzed using nuclear magnetic resonance spectroscopy (NMR). <b>Results/Conclusions:</b> The results demonstrate that the AMDD 3D printing process is well-suited for producing solid dosage forms. Tablets were successfully printed, meeting mass uniformity standards. Adjusting the infill volume from 30% to 100% effectively controlled the drug release rate of the tablets. Solid-state analysis revealed that the AMDD process can produce amorphous solid dispersions with enhanced solubility compared to their crystalline form. The experiments also demonstrated that powders with a particle size of approximately 200 µm can be directly processed using AMDD technology.
format Article
id doaj-art-6ffcd07bae294917b7e6adb54fd09f57
institution Kabale University
issn 1999-4923
language English
publishDate 2024-11-01
publisher MDPI AG
record_format Article
series Pharmaceutics
spelling doaj-art-6ffcd07bae294917b7e6adb54fd09f572024-12-27T14:46:19ZengMDPI AGPharmaceutics1999-49232024-11-011612150110.3390/pharmaceutics16121501Exploring 3D Printing in Drug Development: Assessing the Potential of Advanced Melt Drop Deposition Technology for Solubility Enhancement by Creation of Amorphous Solid DispersionsNabil Lamrabet0Florian Hess1Philip Leidig2Andreas Marx3Thomas Kipping4Merck Life Science KGaA, Frankfurter Straße 250, 64293 Darmstadt, GermanyMerck Life Science KGaA, Frankfurter Straße 250, 64293 Darmstadt, GermanyMerck Life Science KGaA, Frankfurter Straße 250, 64293 Darmstadt, GermanyMerck Life Science KGaA, Frankfurter Straße 250, 64293 Darmstadt, GermanyMerck Life Science KGaA, Frankfurter Straße 250, 64293 Darmstadt, Germany<b>Background:</b> Melt-based 3D printing technologies are currently extensively evaluated for research purposes as well as for industrial applications. Classical approaches often require intermediates, which can pose a risk to stability and add additional complexity to the process. The Advanced Melt Drop Deposition (AMDD) technology, is a 3D printing process that combines the principles of melt extrusion with pressure-driven ejection, similar to injection molding. This method offers several advantages over traditional melt-based 3D printing techniques, making it particularly suitable for pharmaceutical applications. <b>Objectives:</b> This study evaluates the AMDD printing system for producing solid oral dosage forms, with a primary focus on the thermo-stable polymer polyvinyl alcohol (PVA). The suitability of AMDD technology for creating amorphous solid dispersions (ASDs) is also examined. Finally, the study aims to define the material requirements and limitations of the raw materials used in the process. <b>Methods:</b> The active pharmaceutical ingredients (APIs) indometacin and ketoconazole were used, with PVA 4-88 serving as the carrier polymer. Powders, wet granulates, and pellets were investigated as raw materials and characterized. Dissolution testing and content analyses were performed on the printed dosage forms. Solid-state characterization was conducted using differential scanning calorimetry (DSC) and X-ray diffraction (XRD). Degradation due to thermal and mechanical stress was analyzed using nuclear magnetic resonance spectroscopy (NMR). <b>Results/Conclusions:</b> The results demonstrate that the AMDD 3D printing process is well-suited for producing solid dosage forms. Tablets were successfully printed, meeting mass uniformity standards. Adjusting the infill volume from 30% to 100% effectively controlled the drug release rate of the tablets. Solid-state analysis revealed that the AMDD process can produce amorphous solid dispersions with enhanced solubility compared to their crystalline form. The experiments also demonstrated that powders with a particle size of approximately 200 µm can be directly processed using AMDD technology.https://www.mdpi.com/1999-4923/16/12/15013D printingadvanced manufacturingAdvanced Melt Drop Depositionamorphous solid dispersionssolubility enhancement
spellingShingle Nabil Lamrabet
Florian Hess
Philip Leidig
Andreas Marx
Thomas Kipping
Exploring 3D Printing in Drug Development: Assessing the Potential of Advanced Melt Drop Deposition Technology for Solubility Enhancement by Creation of Amorphous Solid Dispersions
Pharmaceutics
3D printing
advanced manufacturing
Advanced Melt Drop Deposition
amorphous solid dispersions
solubility enhancement
title Exploring 3D Printing in Drug Development: Assessing the Potential of Advanced Melt Drop Deposition Technology for Solubility Enhancement by Creation of Amorphous Solid Dispersions
title_full Exploring 3D Printing in Drug Development: Assessing the Potential of Advanced Melt Drop Deposition Technology for Solubility Enhancement by Creation of Amorphous Solid Dispersions
title_fullStr Exploring 3D Printing in Drug Development: Assessing the Potential of Advanced Melt Drop Deposition Technology for Solubility Enhancement by Creation of Amorphous Solid Dispersions
title_full_unstemmed Exploring 3D Printing in Drug Development: Assessing the Potential of Advanced Melt Drop Deposition Technology for Solubility Enhancement by Creation of Amorphous Solid Dispersions
title_short Exploring 3D Printing in Drug Development: Assessing the Potential of Advanced Melt Drop Deposition Technology for Solubility Enhancement by Creation of Amorphous Solid Dispersions
title_sort exploring 3d printing in drug development assessing the potential of advanced melt drop deposition technology for solubility enhancement by creation of amorphous solid dispersions
topic 3D printing
advanced manufacturing
Advanced Melt Drop Deposition
amorphous solid dispersions
solubility enhancement
url https://www.mdpi.com/1999-4923/16/12/1501
work_keys_str_mv AT nabillamrabet exploring3dprintingindrugdevelopmentassessingthepotentialofadvancedmeltdropdepositiontechnologyforsolubilityenhancementbycreationofamorphoussoliddispersions
AT florianhess exploring3dprintingindrugdevelopmentassessingthepotentialofadvancedmeltdropdepositiontechnologyforsolubilityenhancementbycreationofamorphoussoliddispersions
AT philipleidig exploring3dprintingindrugdevelopmentassessingthepotentialofadvancedmeltdropdepositiontechnologyforsolubilityenhancementbycreationofamorphoussoliddispersions
AT andreasmarx exploring3dprintingindrugdevelopmentassessingthepotentialofadvancedmeltdropdepositiontechnologyforsolubilityenhancementbycreationofamorphoussoliddispersions
AT thomaskipping exploring3dprintingindrugdevelopmentassessingthepotentialofadvancedmeltdropdepositiontechnologyforsolubilityenhancementbycreationofamorphoussoliddispersions